Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $9.8 million.

  • Rocket Pharmaceuticals' Share-based Compensation fell 1323.79% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year decrease of 170.01%. This contributed to the annual value of $43.9 million for FY2024, which is 1145.51% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Share-based Compensation stood at $9.8 million for Q3 2025, which was down 1323.79% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Share-based Compensation ranged from a high of $11.3 million in Q2 2024 and a low of $6.3 million during Q1 2022
  • Moreover, its 5-year median value for Share-based Compensation was $9.8 million (2025), whereas its average is $9.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 9944.46% in 2021, then plummeted by 2063.29% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Share-based Compensation (Quarter) stood at $7.0 million in 2021, then skyrocketed by 37.74% to $9.7 million in 2022, then rose by 2.45% to $9.9 million in 2023, then increased by 11.66% to $11.1 million in 2024, then decreased by 11.99% to $9.8 million in 2025.
  • Its Share-based Compensation stands at $9.8 million for Q3 2025, versus $10.9 million for Q2 2025 and $10.3 million for Q1 2025.